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Capsule Summary  37 
Using radiolabeled eosinophils coupled with SPECT/CT the authors quantify eosinophilic 38 
inflammation in the lungs of patients with asthma and focal pulmonary eosinophilic 39 
inflammation, revealing important differences in eosinophil kinetics between obese and non-40 
obese asthmatics. 41 
 42 
Keywords: eosinophils, SPECT/CT, asthma, obesity 43 
 44 
Running Title: Imaging asthmatics using radiolabeled eosinophils 45 
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Abbreviations used: Single photon emission computed tomography (SPECT); fractional exhaled 47 
nitric oxide (FeNO) 48 
 49 
To The Editor: 50 
Eosinophils play an important pathogenic role in pulmonary and systemic conditions 51 
including eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.1,2 While 52 
progress has been made in understanding the mechanisms responsible for the activation of these 53 
cells, existing biomarkers of eosinophilic inflammation are indirect and/or invasive and do not 54 
always correlate with tissue eosinophilia. Hence, there is a need to develop non-invasive 55 
biomarkers of tissue eosinophilia. We have previously demonstrated the capacity of SPECT 56 
(single photon emission computed tomography) to quantify neutrophil uptake into the lungs of 57 
COPD patients.3 We sought to determine whether this methodology could be used to quantify 58 
eosinophil kinetics and pulmonary uptake, which may differ amongst diseases characterized by 59 
eosinophilic inflammation. In particular, the role of the eosinophil in asthma with obesity, a 60 
distinct asthma endotype associated with increased severity,4 is controversial.  We hypothesized 61 
that injection of radiolabeled eosinophils, coupled with SPECT/CT, would reveal changes in 62 
eosinophil kinetics in patients compared to healthy volunteers. 63 
To determine the initial distribution of eosinophils, and to ensure that the re-injected cells 64 
had not been activated, planar gamma camera imaging was performed following injection of 65 
technetium-99m-labeled eosinophils. These scans were performed in healthy volunteers, 66 
asthmatics, and patients with focal eosinophilic inflammation (Fig 1, A; Tables E1 and E2, 67 
Online Repository at www.jacionline.org). The initial transit of radiolabeled eosinophils through 68 
the lung was similar in all subjects (Fig 1, B and C). We generated a ‘first pass’ transit curve to 69 
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calculate the time taken for the initial bolus of eosinophils to transit from the right ventricle 70 
across the pulmonary circulation (Fig E1, Online Repository at www.jacionline.org). This value 71 
was constant across all study groups (Fig E1, B). The 45 minute blood recovery values (Fig 1, D) 72 
did not differ between the study groups and, importantly, were comparable to published levels for 73 
un-manipulated radiolabeled eosinophils from healthy volunteers, indicating the re-injected 74 
eosinophils were non-activated.5 As predicted,5,6 circulating eosinophils accumulated rapidly 75 
within the liver and spleen, most likely within known marginated intra-vascular pools (Fig 1, E-76 
G). 77 
To measure the time-dependent uptake of radiolabeled eosinophils from the blood into the 78 
lungs (‘pulmonary uptake’), serial images were acquired using SPECT/CT (Fig 1, H) and Patlak-79 
Rutland analysis undertaken (Fig E2, Online Repository at www.jacionline.org). As shown in Fig 80 
1, I pulmonary uptake was significantly increased in focal eosinophilic inflammation patients 81 
(0.002 ml/min/ml; P=0.02) compared to healthy volunteers (0.0003 ml/min/ml). There was a 82 
trend towards increased pulmonary uptake in asthmatics (0.0008 ml/min/ml; P=0.14). However, 83 
conversion of this rate of uptake to an absolute whole lung eosinophil migration value by 84 
multiplying with the peripheral blood eosinophil count revealed the full extent of eosinophil 85 
accumulation by the lungs; patients with focal eosinophilic lung inflammation and asthmatic 86 
subjects had higher rates of eosinophil migration than healthy volunteers (32 eosinophils/min/ml) 87 
(Fig 1, J). The extent of eosinophil migration in asthmatics did not correlate with lung function or 88 
FeNO (Figs E3 and E4, Online Repository at www.jacionline.org).  89 
To determine whether this technique could reveal differences in eosinophil kinetics 90 
between asthma endotypes we stratified asthmatics as obese (BMI ≥30 kg/m2) or non-obese (BMI 91 
<30 kg/m2) (Fig 2, A; Table E3, Online Repository at www.jacionline.org), and compared their 92 
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 5
eosinophil uptake. As shown in Fig 2, B, pulmonary uptake was increased in obese asthmatics 93 
(0.001 ml/min/ml) compared to non-obese asthmatics (0.0003 ml/min/ml; P=0.02). This effect 94 
was not explained by an increase in the early retention of eosinophils in the lung as the first pass 95 
mean transit time was faster in obese asthmatic eosinophils compared to non-obese asthmatic 96 
eosinophils (P=0.038) (Fig 2, C). Furthermore the 45-minute post-injection eosinophil recovery 97 
values and peripheral blood eosinophil counts were also similar (Fig E4, A and B, Online 98 
Repository at www.jacionline.org). In a parallel but separate group of asthmatic subjects (Fig 2, 99 
D), stratified in an identical manner to the SPECT/CT cohort, the bronchial submucosal 100 
eosinophil count was significantly elevated in obese compared to non-obese asthmatics 101 
(P=0.024) (Fig 2, E and F). The epithelial eosinophil count, sputum eosinophil count, peripheral 102 
blood eosinophil count, FeNO levels and IgE levels were not significantly different between the 103 
asthmatics with and without obesity (Figs E3 and E4, Online Repository at www.jacionline.org).  104 
The impact of anti-eosinophil therapies on eosinophil trafficking is poorly understood. 105 
Inhaled corticosteroids are the mainstay treatment for asthma and reduce the number of 106 
eosinophils in sputum and bronchial biopsies. Biological therapies such as mepolizumab,2 reduce 107 
blood and lung eosinophil counts, but their effects upon eosinophil trafficking are unknown. We 108 
anticipate that in vivo imaging of eosinophils will inform the development of these therapies, and 109 
shed light on the mechanisms controlling eosinophil migration.  110 
We quantified eosinophil uptake from the blood to the lungs and demonstrated increased 111 
eosinophil migration to the lungs in our asthmatic cohort relative to healthy controls. Although 112 
eosinophil migration in part reflects the peripheral blood eosinophil count, our methodology 113 
localizes inflammation and quantifies the migration to the ‘whole lung’ parenchyma, providing 114 
information that cannot be obtained from the blood count alone.7 We observed that eosinophil 115 
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uptake is enhanced in obese asthmatics compared to non-obese asthmatics, in agreement with our 116 
histology study. These results challenge the current dogma that asthma with obesity is associated 117 
with non-eosinophilic inflammation (demonstrated by a low sputum eosinophil count),4 and we 118 
propose that the bronchial eosinophil count and sputum eosinophil count are uncoupled.8   119 
Our study has some limitations. Firstly, 50% of our asthmatic cohort (studied in the 120 
imaging protocol) was recruited from primary care, and hence had not undergone in-depth 121 
phenotyping, and only 3 asthmatics had a clearly eosinophilic phenotype based on FeNO and 122 
peripheral eosinophil count. Secondly, although we have previously published a rigorous 123 
assessment of the re-injected eosinophils,5 we cannot absolutely exclude subtle changes in cell 124 
function due to cell isolation and labeling.  125 
In conclusion, SPECT/CT imaging using radiolabeled eosinophils provides evidence that 126 
eosinophil uptake can be quantified in the lungs and is enhanced in obese asthmatics compared to 127 
non-obese asthmatics. This finding has important implications for the role of eosinophils in obese 128 
asthma and for selecting patients for targeted therapy in the context of type 2 inflammation. 129 
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 208 
Figure Legends 209 
FIG 1. Early organ distribution and lung uptake of technetium-99m-labeled eosinophils. (A) 210 
Participants in the scanning protocols. (B) Time-course of radioactivity in the right lung 211 
following re-injection of technetium-99m-labeled eosinophils. (C) Half-life of technetium-99m-212 
labeled eosinophil activity in the lungs. Median with interquartile range (Mann-Whitney U test). 213 
(D) Proportion of technetium-99m-labeled eosinophils remaining in the blood 45 min post re-214 
injection. Median with interquartile range (Mann-Whitney U test). (E) Gamma camera image 5 215 
min (left) and 40 min (right) after re-injection of technetium-99m-labeled eosinophils in a healthy 216 
volunteer. Posterior images show accumulation in the right lung (RL), left lung (LL), liver (L) 217 
and spleen (S). (F and G) Distribution of radioactivity in the liver (green) and spleen (black) 218 
following re-injection of technetium-99m-labeled eosinophils. Data show median with 219 
interquartile range in healthy volunteers (F) and asthmatics (G); *P<0.05, **P<0.01 and 220 
***P<0.001 compared with peak liver or peak spleen radioactivity (Kruskal-Wallis with Dunn’s 221 
post-test). †P=0.009 compared with healthy liver radioactivity at 17 min (Mann-Whitney U test). 222 
(H) Transaxial SPECT images. Images show accumulation in the right lung and left lung 223 
(outlined by white lines) 6 hours after re-injection. Pulmonary uptake (I) and pulmonary 224 
migration (J) of technetium-99m-labeled eosinophils. Median with interquartile range (Mann-225 
Whitney U test).   226 
FIG 2. SPECT/CT quantification of pulmonary eosinophil uptake and bronchial biopsy 227 
eosinophil counts in obese and non-obese asthmatics. (A) Participants in the scanning cohort. (B) 228 
Pulmonary eosinophil uptake of asthmatics, stratified by body mass index as obese or non-obese. 229 
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Mean ± SEM (unpaired Student’s t-test). (C) Transit time across the pulmonary circulation. 230 
Median with interquartile range of 10 subjects (Mann-Whitney U test). (D) Participants in the 231 
bronchial biopsy cohort. (E) Bronchial biopsy photomicrograph from an obese asthmatic 232 
showing IgG1 control (top) and major basic protein (bottom) stained eosinophils, scale bar 233 
indicates 50 µm. (F) Quantification of bronchial submucosal eosinophil count from asthmatics, 234 
stratified by body mass index. Median with interquartile range (Mann-Whitney U test). 235 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
p=0.92
p=0.99
*
L
a
b
e
lle
d
 E
O
S
 r
e
m
a
in
in
g
in
 b
lo
o
d
 a
t 
4
5
 m
in
 (
%
)
O
rg
a
n
 r
a
d
io
a
c
tiv
ity
E
B
Healthy Asthma
F
Figure 1
D
LL RL
S
L
0 10 20 30 40
0
20
40
60
80
100
Healthy 
Asthma 
C
o
u
n
ts
 i
n
 l
u
n
g
 (
%
 m
a
x
im
iu
m
)
A
Healthy Asthma Focal
0
500
1500
L
u
n
g
 d
is
tr
ib
u
tio
n
 t
1
/2
 (
s
e
c
o
n
d
s
)
Time (minutes)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
2 6 8 104
HoursMinutes
0 10 20 30 40
(c
o
u
n
ts
/p
ix
e
l/M
B
q
)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 10 20 30 40 2 6 8 104
Minutes Hours
O
rg
a
n
 r
a
d
io
a
c
tiv
ity
(c
o
u
n
ts
/p
ix
e
l/M
B
q
)
Time Time
p=0.88 p=0.35
C
0
30
10
20
Healthy Asthma Focal
*
***
Liver
Spleen
Liver
Spleen
*
***
**
p=0.2440
1000
†
S
G
Healthy
H
Asthmatic
RL LLRLLL
I
0
200
400
600
1000
9000
17000
25000
Asthma Healthy Focal
p=0.03
(e
o
s
in
o
p
h
ils
/m
in
/m
l)
E
o
s
in
o
p
h
il 
m
ig
ra
tio
n
0.0000
0.0005
0.0010
0.0015
0.0020
0.0030
0.0050
0.0070
0.0090
E
o
s
in
o
p
h
il 
u
p
ta
k
e
(s
lo
p
e
/In
te
rc
e
p
t)
(m
l/m
in
/m
l)
Asthma Healthy Focal
p=0.02
p=0.14
S
p=0.01J
LL
Healthy
(n=8)
Asthmatic
(n=8)
Focal
(n=8)
Dynamic and SPECT/CT
scans
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
< 30  30
0
10
20
30
40
50
S
u
b
m
u
co
s
a
l e
o
s
in
o
p
h
ils
 (
ce
lls
/m
m
2
)
p=0.024
B
Figure 2
<30 30
-0.0005
0.0000
0.0005
0.0010
0.0015
0.0020 p=0.020
A
E
o
s
in
o
p
h
il 
u
p
ta
k
e
(s
lo
p
e
/In
te
rc
e
p
t)
 (
m
l/m
in
/m
l)
BMI (kg/m2)
M
e
a
n
 t
ra
n
s
it 
tim
e
 (
s
)
D
C
BMI (kg/m2)
Isotype control
MBP+
10
15
20
25
30
35
E
<30 30
BMI (kg/m2)
p=0.038
F
Dynamic and  
SPECT/CT scans
Asthmatic
(n=14)
Obese
(n=7)
Non-obese
(n=7)
Bronchial biopsy
cohort
Asthmatic
(n=34)
Obese
(n=17)
Non-obese
(n=17)
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
 1 
 
In vivo imaging reveals increased eosinophil uptake in the 
lungs of obese asthmatics 
 
Neda Farahi1a*, Chrystalla Loutsios1a, Nicola Tregay1, Adam K.A. Wright2, Rachid Berair2,  
Laurence S.C. Lok1, Daniel Gillett3, Ian Cullum3, Rosalind P Simmonds1, Charlotte Summers4,  
Anna Wong3, Chandra K. Solanki3, John Buscombe3, Pee Hwee Pang2, Arthikkaa Thavakumar2,  
A. Michael Peters5, Christopher E. Brightling†2, Alison M. Condliffe†1, and Edwin R. Chilvers†1 
 
1Division of Respiratory Medicine, Department of Medicine, University of Cambridge School of Clinical 
Medicine, Cambridge, UK. 2Institute for Lung Health, NIHR Respiratory Biomedical Research Unit, 
Leicester, UK. 3Department of Nuclear Medicine, Addenbrooke’s Hospital, CUHNHSFT, Cambridge, UK. 
4Division of Anaesthesia, Department of Medicine, University of Cambridge School of Clinical Medicine, 
Cambridge, UK. 5Division of Clinical and Laboratory Investigation, Brighton and Sussex Medical School, 
Brighton, UK. 
 
Online Data Supplement
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
 2
Methods 
Planar and SPECT/CT imaging of radiolabeled eosinophils 
Participants 
The study was approved by the Cambridgeshire 2 Research Ethics Committee (09/H0308/119) and the 
Administration of Radioactive Substances Advisory Committee of the United Kingdom (83/3130/25000); all 
subjects gave written informed consent. The subjects comprised 8 healthy individuals, 15 patients with 
asthma and 3 patients with focal pulmonary eosinophilic inflammation (eosinophilic pneumonia, ANCA-
positive vasculitis and IgG4-related disease) (tables E1 and E2). Asthma was diagnosed by a physician based 
on symptoms and asthmatics were classified according to British Thoracic Society (BTS) Step classification.  
Eosinophil labeling  
Eosinophils were isolated from 160 ml of autologous venous blood as described previously.E1 The 
eosinophils were labeled with technetium-99m-hexamethylpropyleneamine oxime (HMPAO) (GE 
Healthcare Buckinghamshire, United Kingdom), before re-injection into volunteers. The ex-vivo preparation 
time was 3.75 hours. Blood was collected at intervals up to 9 hours post-injection and radioactivity 
measured in a gamma counter. The injected activities of the radiolabeled cells were not significantly 
different between the healthy and asthmatic patients (data not shown).    
Dynamic, static and SPECT/CT imaging 
Volunteers were positioned in a double-headed SPECT/CT camera (GE Discovery 670, GE Healthcare), 
fitted with low-energy, parallel-hole collimators. After bolus intravenous injection of technetium-99m-
labeled eosinophils (mean 120 MBq; range 46-199 MBq injected/subject), the activities in the chest and 
upper abdomen were recorded as previously described.E1 SPECT images were acquired over 20 minutes at 
45 minutes, 2, 4, 6, and 9 hours following re-injection. A CT scan was performed at the end of the 45 min 
SPECT acquisition for anatomical co-registration with SPECT. To generate time-activity curves, regions of 
interest (ROIs) were drawn over the right lung, the liver and spleen using Xeleris software (Version 3.1, GE 
Healthcare). Mean counts per pixel or voxel in these ROIs were recorded and corrected for physical decay 
of the radionuclide. To calculate the first pass transit time of eosinophils a gamma variate fit was generated 
from the mean counts per pixel or voxel in the lung.E2 Gamma variate fit was performed on 15/22 subjects 
(Fig E1), as it required a minimum number of data points between 0 and 120 seconds after re-injection of 
the radiolabeled cells. 
Patlak-Rutland analysis 
Peripheral blood samples were taken at 2, 4, 6, 8, 10, 15, 30, 45, 90, 120, 240, 360, and 540 min post-
injection and radioactivity measured in a gamma counter. ROIs were drawn over the lung on transaxial 
sections of the SPECT images at each time point (Fig E2) and average counts per voxel for each lung 
determined. Patlak-Rutland analysis was used to measure pulmonary eosinophil uptake per unit pulmonary 
eosinophil distribution volume by dividing the plot gradient by the intercept, as previously described.E3–5 
Total eosinophil migration per unit pulmonary distribution volume was calculated by multiplying the 
eosinophil uptake by the average peripheral blood eosinophil count of each subject. These measures of 
eosinophil blood/lung gradient are independent of the administered activity.   
 
Quantitation of submucosal eosinophils in obese and non-obese asthmatics  
Participants  
Data were obtained from the pre-treatment investigations including bronchial biopsies of 61 subjects 
participating in a randomised, double-blind, placebo-controlled trial of fevipiprant, a prostaglandin D2 
receptor 2 antagonist.E6 All subjects provided written informed consent. The study was approved by the 
Leicestershire, Northamptonshire, and Rutland Research Ethics Committees (11/EM/0402) and the UK 
Medicines and Healthcare Products Regulatory Agency. Details of the patient characteristics are provided in 
Table E3. 
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Quantitation of submucosal eosinophils in obese and non-obese asthmatics  
Sputum, blood, and FeNO sample collection 
Induced sputum (n=59), blood (n=61), endobronchial biopsy (n=34), and fractional exhaled nitric oxide 
(n=60) were collected from visit 3 of the pre-treatment phase of the fevipiprant trial.E6 Absolute eosinophil 
numbers in induced sputum and blood were determined as described.E6 A cross-sectional analysis of this 
data, comparing asthma patients with and without obesity, was performed and presented here for the first 
time.   
Measurement of submucosal eosinophils 
Biopsy specimens were embedded in glycol methacrylate and 2µm sections stained with haematoxylin and 
eosin and anti-eosinophil major basic protein (MBP) (Clone BMK-13, Monosan, Uden, The Netherlands) as 
previously detailed.E7 Eosinophils were expressed as cells/mm2 of lamina propria and as cells/mm2 of 
epithelium. 
Statistical analysis 
Blood eosinophil recovery values were calculated as described previously.E8 Statistical analyses were 
performed using GraphPad Prism (6.0d, San Diego, CA, USA) as detailed in the figure legends. Data was 
tested for normality using the Shapiro-Wilk test. For non-parametric data a Mann-Whitney U-test was 
applied and for parametric data a Student’s t-test was used. For categorical data, a Fisher’s exact test was 
used. A P value of <0.05 was considered significant. Values are expressed as mean ± SEM or the median 
and inter-quartile range.  
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Supplementary Figure Legends 
 
Figure E1. Technetium-99m-labeled eosinophil transit across the lung. (A) Representative gamma variate 
function fitted to a time-activity curve. A gamma variate was fitted using a least squares residual method to 
simulate the first pass time curve for eosinophils across the lung. Data from a single representative 
experiment (healthy control). (B) Transit time for eosinophils to cross from the right ventricle into the 
pulmonary circulation for healthy volunteers, asthmatics and focal eosinophilic inflammation patients. Data 
represent the median with interquartile range for 10 asthmatics, 5 healthy volunteers, and 3 patients with 
focal pulmonary eosinophilic inflammation. P values calculated using Mann-Whitney U test. 
Figure E2. SPECT image analysis of the lung regions of interest (ROI). Examples of SPECT images 
corresponding to lower, middle, and upper lung sections 6 hours post re-injection of technetium-99m-
labeled eosinophils in an healthy volunteer (left panel) and an asthmatic patient (right panel). White lines 
represent lung ROI. At each time point ROI were drawn from sections of lung images. Each lung section 
was 4.42 mm thick and, depending on the size of the lung, the total number of sections drawn ranged from 
10-15 at the early time-points (45 min post re-injection) to 15-30 at time-points 6 hours and later. The first 
lung ROI was drawn from the base of the lung, which was always at least four sections above the 
liver/spleen to avoid any scatter from these organs. Sequential ROI were then drawn up to the top of the 
lung. When drawing the ROI, care was taken to avoid the signal from the mediastinum and bone marrow 
(vertebra, sternum and ribs). For consistency, the saturation of the scan was adjusted at each time point and 
for each volunteer such that the vertebral body colour had changed from blue to yellow, and then to the first 
hint of white. This saturation was chosen as it gave the optimal contrast between the lung and thoracic bony 
skeleton. The counts from each lung section were summed and expressed as counts/voxel prior to Patlak-
Rutland analysis. 
Figure E3. Correlations between radiolabeled eosinophil uptake or eosinophil migration into the lung with 
FEV1 (% predicted), FVC (% predicted), FeNO, Z-score (FEV1/FVC) and peripheral blood eosinophil 
count. Correlations between radiolabeled eosinophil uptake with (A) Peripheral blood eosinophil count, (B) 
FEV1, (C) Z-score (FEV1/FVC), (D) FVC (% predicted), and (E) FeNO. Correlations between radiolabeled 
eosinophil eosinophil migration and (F) FEV1 (% predicted), (G) FEV1/FVC, (H) FVC (% predicted), and 
(I) FeNO. FEV1 = forced expiratory volume in one second, FVC = forced vital capacity, FeNO = fractional 
exhaled nitric oxide and PPB = parts per billion. Both FeNO and spirometry results were only available for 
22/26 subjects. P values calculated using Spearman correlation analysis (A and G) or Pearson correlation 
analysis (B-F and H-I). 
Figure E4. Comparison of 45 min blood recovery values and peripheral blood eosinophil count in the obese 
and non-obese asthmatic SPECT/CT cohort, and peripheral blood eosinophil count, epithelial and sputum 
eosinophil numbers, peripheral eosinophil blood count, FeNO levels and IgE levels in the obese and non-
obese asthmatic bronchial biopsy cohort. Subjects with asthma are classified by their body mass index 
(kg/m2) into non-obese (<30 kg/m2) and obese (≥30 kg/m2). (A) Proportion of injected technetium-99m-
labeled eosinophils remaining in the blood at 45 min post re-injection. Data represent the mean ± SEM of 7 
experiments for non-obese asthmatics and 7 experiments for obese asthmatics. P values calculated using 
unpaired Student’s t-test. (B) Peripheral blood eosinophil counts in SPECT/CT subjects with asthma 
stratified by body mass index as described above. Data represent the median with interquartile range of 7 
subjects for non-obese asthmatics and 7 subjects for obese asthmatics. P values calculated using Mann-
Whitney U test. (C) Epithelial eosinophil counts, (D) sputum eosinophil counts, (E) peripheral blood 
eosinophil counts, (F) FeNO, and (G) IgE levels in the obese and non-obese bronchial biopsy cohort. Data 
represent the median with interquartile range of 12-33 subjects for non-obese asthmatics and 13-28 subjects 
for obese asthmatics. P values calculated using Mann-Whitney U test. 
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Table E1. Demographic and lung function of study subjects in the planar and SPECT/CT protocol. FeNO 
and spirometry results were available for 22/26 subjects. Data are presented as median (interquartile range) 
or *mean (standard error of mean [SEM]). P values were compared to the healthy volunteer values, using 
Mann-Whitney U test or Student’s t-test. FEV1 = forced expiratory volume as % predicted. FVC = forced 
vital capacity. FeNO = fractional exhaled nitric oxide. PPB = parts per billion. Spirometric measurements 
were calculated using the European Community for Coal and Steel (ECSC) protocol with Z-scores from the 
Global Lung Initiative site (http://gligastransfer.org.au/calcs/spiro.html).E9 American Thoracic Society 
clinical practice guidelines state that low FeNO corresponds to <25 PPB, intermediate FeNO between 25 
PPB and 50 PPB, and high FeNO >50 PPB in adults. Atopy status was assessed by a positive skin prick test 
to one or more allergens or a clear history of seasonal allergic rhinitis. 
 
 Healthy Asthma Focal eosinophilic 
inflammation 
(N) 8 15 3 
Gender F/M 5/3 7/8 0/3 
Age (years)* 64 (4) 60 (2) 57 (6) 
Peripheral blood 
eosinophil count (x109/l)  
0.11 (0.08 to 0.14) 0.27 (0.16 to 0.54, P =0.0008) 0.85 (0.72 to 2.60, 
P =0.012) 
BMI (kg/m2)* 25 (1.46) 28 (0.82) (P=0.04) 22 (1.76) 
FeNO (PPB)  14.0 (8.8 to 23.0) 25.5 (13.5 to 35.0) 11.0 (8.0 to 35.0) 
FEV1 (% pred)  99.0 (88.0 to 112.0) 82.0 (70.5 to 90.3, P =0.015) 62.0 (52.0 to 75.0, 
P=0.017) 
FEV1/FVC 72.0 (62.0 to 79.0) 64.5 (57.3 to 78.3) 60.0 (56.0 to 64.0) 
FEV1/FVC 
Z-score 
-1.16 (-1.92 to -0.23) -0.13 (-4.09 to -0.03) -2.24 (-2.47 to -
2.01) 
Smoking status 
(current/previous/never) 
0/2/5 0/7 (4 obese and 3 non-obese)/8 (3 
obese and 4 non-obese)  
1/1/1 
Atopic/non-atopic 0/5 10 atopics (5 obese and 5 non-
obese)/4 non-atopic (2 obese and 2 
non-obese) 
1/3 
Co-morbidities 
(number of patients) 
Cardiovascular disease 
(3), depression (1) and 
4 without any stated co-
morbidities  
Cardiovascular disease (3), 
gastrointestinal disease (2), 
hypothyroidism (1) arthritis (1), 
cirrhosis (1), anxiety (1), hernia (1), 
type 2 diabetes (1) and 7 without any 
stated co-morbidities 
Asthma (1); small 
joint 
polyarthropathy (1) 
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Table E2. BTS Step classification and medication of asthmatic participants in the planar dynamic and 
SPECT/CT protocol. BDP = beclometasone dipropionate 
 
BTS Asthma Step 
(number of patients 
in each category) 
Median 
(range) daily 
ICS dose  
(µg BDP 
equivalent)  
Oral daily 
prednisolone 
dose 
(mg) 
Median (range) long-acting β2-
adrenoceptor dose/day  
(µg) 
Therapies in 
addition to prn 
salbutamol 
(number of 
patients) 
   Formoterol 
 
Salmeterol 
 
 
Step 1 (3) 0 0 0 0 Aminophylline (1) 
Step 2 (1) 400  0 0 0 None 
Step 3 (6) 800 (700 to 
800) 
0 24 (24 to 24) 0 Montelukast (2) 
Step 4 (3) 1200 (1000 to 
1200) 
0 0 75 (50 to 100) Montelukast (1) 
Tiotropium (1) 
Step 5 (2) 800 (800 to 
800) 
7.5 (5 to 10) 24 (24 to 24) 0 Tiotropium (2) 
Montelukast (1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
 7
Table E3. Clinical characteristics of the study participants from whom bronchial biopsies were collected. 
Data from 33 non-obese patients and 28 obese patients based on a BMI threshold of 30 are presented as 
median (interquartile range) unless otherwise stated; P values calculated using Mann-Whitney U test or, for 
categorical data, using a Fisher’s exact test. *mean (standard error of mean [SEM]); +Beclomethasone 
dipropionate equivalent. BMI = Body mass index. ECP = Eosinophil cationic protein. FeNO = fractional 
exhaled nitric oxide. PPB = parts per billion. IgE = Immunoglobulin E.  
 
a. n =34.  b. n =25. c. n =59. d. n =56. e. n =60 
 
 
 
 
 
 
 
 
 
 
Non-obese 
BMI <30 
 
Obese 
BMI ≥30 
 
 
P value 
 
n 
Age (years)* 51 (3) 49 (2) 0.4652 61 
Male, n (%) 20 (60.6) 11 (39.3) 0.1261 61 
BMI (kg/m2)* 26 (0.36) 36 (0.84) <0.0001 61 
Daily inhaled corticosteroid dose (mcg/day)* + 1267 (101) 1504 (98) 0.2384 61 
Submucosal eosinophils (cells/mm2) 8.58 (5.91 to 18.84) 16.23 (12.37 to 29.27) 0.0238 34 
Epithelial eosinophils (cells/mm2) 0 (0 to 10.5) 3.9 (0 to 6.3) 0.4919 25 
Sputum eosinophil count (%) 5.8 (1.9 to 32.8) 4 (1.8 to 10.2) 0.1444 59 
Peripheral blood eosinophil count (109/l) 0.34 (0.21 to 0.60) 0.25 (0.17 to 0.47) 0.2134 61 
ECP (ng/ml) 31.9 (19.5 to 54.0) 26.8 (14.6 to 55.2) 0.5377 56 
FeNO (PBB) 38.3 (19.5 to 64.8) 27.8 (18.1 to 56.9) 0.3512 60 
Total IgE (kU/l) 172 (77 to 440) 158 (90 to 352) 0.8120 59 
Atopic/non-atopic 29/4 26/2 0.6781 61 
BTS Asthma Step 4 (4 to 4) 4 (4 to 5) 0.0927 61 
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